Guard Therapeutics: Q3 Review
Research Note
2020-11-18
16:03
Redeye notes that the Q3 report from Guard did not include any major surprises. We give a brief comment on the report and reiterate our Base case of SEK 3.0 per share.
LS
Ludvig Svensson
Disclosures and disclaimers